Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT‐1 trial

医学 析因分析 超重 2型糖尿病 肥胖 糖尿病 内科学 内分泌学
作者
Emily R. Hankosky,Hui Wang,Lisa M. Neff,Hong Kan,Fangyu Wang,Nadia N. Ahmad,Adam Stefański,W. Timothy Garvey
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:25 (12): 3748-3756 被引量:16
标识
DOI:10.1111/dom.15269
摘要

Abstract Aim We assessed the impact of tirzepatide on 10‐year predicted risk of developing type 2 diabetes (T2D) among participants in the SURMOUNT‐1 trial. Materials and Methods In this post hoc analysis of SURMOUNT‐1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10‐year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or 15 mg tirzepatide or placebo. Mean changes in risk scores from baseline to weeks 24 and 72 were compared between tirzepatide and placebo groups. Subgroup analyses were conducted based on participants' glycaemic status and body mass index at baseline. Results Mean baseline T2D predicted risk scores did not differ between tirzepatide and placebo groups (range: 22.9%‐24.3%). At week 72, mean absolute T2D predicted risk score reductions were significantly greater in tirzepatide groups (5 mg, 12.4%; 10 mg, 14.4%; 15 mg, 14.7%) versus placebo (0.7%). At week 72, median relative predicted risk reductions following tirzepatide treatment ranged from 60.3% to 69.0%. For participants with and without prediabetes, risk reductions were significantly greater in tirzepatide groups versus placebo. At week 72, participants with prediabetes (range: 16.0%‐20.3%) had greater mean risk score reductions from baseline versus those without prediabetes (range: 10.1%‐11.3%). Across body mass index subgroups, mean reductions from baseline were significantly greater in tirzepatide groups versus placebo. Conclusion Tirzepatide treatment significantly reduced the 10‐year predicted risk of developing T2D compared with placebo in participants with obesity or overweight, regardless of baseline glycaemic status.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
稳重乌冬面完成签到 ,获得积分10
1秒前
一苇以航完成签到 ,获得积分10
2秒前
戚雅柔完成签到 ,获得积分10
2秒前
vsvsgo完成签到,获得积分10
3秒前
米奇完成签到 ,获得积分10
3秒前
加一点荒谬完成签到,获得积分10
3秒前
3秒前
一一一给轻松白桃的求助进行了留言
5秒前
zz2905完成签到,获得积分10
5秒前
小超人完成签到 ,获得积分10
6秒前
香蕉初瑶完成签到,获得积分10
6秒前
meimei完成签到 ,获得积分10
6秒前
儒雅的菠萝吹雪完成签到,获得积分10
7秒前
7秒前
8秒前
水寒完成签到,获得积分10
8秒前
拉长的念珍完成签到,获得积分10
9秒前
大气夜山完成签到 ,获得积分10
9秒前
Tristan完成签到 ,获得积分10
11秒前
我思故我在完成签到,获得积分10
11秒前
12秒前
何浏亮完成签到,获得积分10
13秒前
阿成完成签到,获得积分10
13秒前
Pauline完成签到 ,获得积分10
13秒前
14秒前
微笑的语芙完成签到,获得积分10
14秒前
14秒前
小背包完成签到 ,获得积分10
14秒前
水寒发布了新的文献求助10
16秒前
希望天下0贩的0应助17采纳,获得10
16秒前
yu完成签到 ,获得积分10
16秒前
钟瑞乾完成签到,获得积分10
16秒前
花痴的电灯泡完成签到,获得积分10
17秒前
虚心念桃完成签到,获得积分10
18秒前
jiaolulu发布了新的文献求助10
19秒前
zyw完成签到 ,获得积分10
19秒前
ironsilica完成签到,获得积分10
22秒前
23秒前
被动科研完成签到,获得积分10
25秒前
斗牛的番茄完成签到 ,获得积分10
26秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022